Russia: Sputnik Light COVID-19 vaccine 70% effective vs. Delta variant

enablePagination: false
maxItemsPerPage: 10
totalITemsFound:
maxPaginationLinks: 10
maxPossiblePages:
startIndex:
endIndex:

Metro Manila (CNN Philippines, October 14) — The single-dose Sputnik Light COVID-19 vaccine “has demonstrated 70% efficacy” against the Delta variant “during the first three months after vaccination,” according to Russia’s sovereign wealth fund.

In a statement released on Wednesday, the Russian Direct Investment Fund (RDIF) said based on analysis conducted, “the vaccine is 75% effective among subjects under the age of 60.”

“The vaccine provides flexibility in immunizing the population, contributing to the formation of primary immunity and effective re-vaccination for recipients who originally received a different vaccine,” said RDIF CEO Kirill Dmitriev.

Sputnik Light also demonstrated “superior efficacy” compared with two-dose vaccines, which have shown waning efficacy against the Delta variant to less than 50% five months after administration, RDIF said.

“Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations,” it added.

The data collected in July 2021 in Moscow was based on 28,000 participants who received Sputnik Light and compared with a control group of 5.6 million unvaccinated individuals.

Developer Gamaleya Institute submitted the findings to medRxiv for publication this week.

Sputnik Light is based on the human adenovirus serotype 26, the first component of the two-dose Sputnik V.

Citing real-world data, RDIF said the single-dose vaccine has been proven safe and effective after it demonstrated 78.6-83.7% efficacy among the elderly as reported health authorities from Argentina and 93.5% efficacy based on Paraguay’s ongoing vaccination program.

There are also ongoing studies on to evaluate immune response and safety of combining Sputnik Light with the vaccines developed by AstraZeneca, Sinopharm, and Moderna.

“Initial results of the study confirm a high safety profile of combinations with no serious adverse events related to vaccination,” RDIF noted.

“Efficacy of one-shot Sputnik Light as a booster against Delta variant for other vaccines will be close to the efficacy against the Delta variant of the Sputnik V vaccine: over 83% against infection and over 94% against hospitalization,” it added.

The Philippine Food and Drug Administration granted Gamaleya emergency use authorization for Sputnik Light on Aug. 23.

Vaccine czar Carlito Galvez Jr. said last month that the government would try to renegotiate the purchase of 10 million doses of Sputnik V to shift to Sputnik Light since it is easier to deploy.

So far, the country has received over 87 million doses of COVID-19 vaccines, while more than 23 million individuals have received full protection from the coronavirus.